Skip to main content
An official website of the United States government
Email

Marker Discovery and Validation

The Diagnostic Biomarkers and Technologies Branch (DBTB) supports research that correlates molecular properties of tumors with important clinical characteristics of people with cancer to identify new cancer markers. Approaches may include the use of genomic, pathologic, and proteomic technologies, including:

  • Comparative genomic hybridization (CGH)
  • Single nucleotide polymorphism (SNP) analysis
  • Epigenetic analysis
  • cDNA arrays
  • mRNA splicing analysis
  • DNA mutation analysis
  • miRNA expression analysis
  • immunohistochemical analysis (IHC)
  • in situ hybridization
  • protein arrays studies
  • MALDI-TOF analysis

Studies may include the use of human tissue samples, tissue microarrays, human cancer cell lines, human tumor xenografts, and animal models. Studies are supported through investigator-initiated R01 applications. 

Experimental Studies of Interest

  • Cancer Detection
  • Cancer Diagnosis
  • Disease Progression
  • Disease Recurrence
  • Patient Survival
  • Response to Therapy
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Marker Discovery and Validation was originally published by the National Cancer Institute.”

Email